📇 Rhumatologue · PANTIN · (93) · Libéral

M LOUIS AIM

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
78.3 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PANTIN (93)LibéralRPPS 10001090264

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR LOUIS AIM
31 AVENUE JEAN LOLIVE, 93500 PANTIN
☎ 48918305Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

The Direct Medical Cost of Essential Tremor

Neuroepidemiology · 2025

📚 7 citations🎯 RCR 3.59

Lire l'abstract Crossref ↓

Objectives: The aim of the study was to determine the direct medical cost of illness from essential tremor (ET) from a patient perspective. Methods: Secondary data from the Optum’s de-identified Clinformatics® Data Mart Database from 2018–2019 were used to assess medical resource utilization and costs. Propensity score matching was used to match patients aged 40+ to statistically similar controls. Generalized linear models were used to estimate average, adjusted total costs of care per year, by healthcare setting, and provider specialty. Results: The final sample included 41,200 patients with at least one ET claim and 36,871 matched patients. Overall, ET patients aged 40+ had about USD 28,217 in direct medical costs per year, which was about USD 1,601 more than matched comparisons (p < 0.001). This was driven by greater number of outpatient visits overall and with specialists. Extrapolating the estimates from our study and pairing them with published age-specific disease prevalence statistics for ET, we calculated an annual cost for direct medical care of ET patients aged 40+ to be about USD 9.4 billion. Conclusion: The estimated direct medical costs among adults aged 40+ with an ET diagnosis aggregated to the population level are nontrivial.

External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab

Gut · 2024

📚 7 citations🎯 RCR 1.54🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ObjectiveIn patients with Crohn’s disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn’s disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (≤6 months) and mid/long-term relapse (>6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).DesignIn SPARE, patients with CD in sustained steroid-free clinical remission and on combination therapy were randomly allocated to three arms: continuing combination therapy, stopping infliximab or stopping immunosuppressant. In the baseline serum of the STORI and SPARE (arm stopping infliximab) cohorts, we studied 202 immune-related proteins. The proteins associated with time to relapse (univariable Cox model) were compared between STORI and SPARE. The discriminative ability of biomarkers (individually and combined in pairs) was evaluated by the c-statistic (concordance analysis) which was compared with C-reactive protein (CRP), faecal calprotectin and a previously validated model (CEASE).ResultsIn STORI and SPARE, distinct blood protein profiles were associated with the risk of short-term (eg, high level: CRP, haptoglobin, interleukin-6, C-type lectin domain family 4 member C) and mid/long-term relapse (eg, low level: Fms-related tyrosine kinase 3 ligand, kallistatin, fibroblast growth factor 2). At external validation, the top 10 biomarker pairs showed a higher c-statistic than the CEASE model, CRP and faecal calprotectin in predicting short-term (0.76–0.80 vs 0.74 vs 0.71 vs 0.69, respectively) and mid/long-term relapse (0.66–0.68 vs 0.61 vs 0.52 vs 0.59, respectively).ConclusionIn patients with CD stopping infliximab, we confirm that the risk of short-term and mid/long-term relapse is associated with distinct blood protein profiles showing the potential to guide infliximab withdrawal.Trial registration numberNCT00571337andNCT02177071.

State-of-the-art of multidisciplinary approach of bone metastasis-directed therapy: review and challenging questions for preparation of a GEMO practice guidelines

Cancer metastasis reviews · 2025

📚 6 citations🎯 RCR 2.87🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Bone is a common secondary site of dissemination during the course of cancer. Bone metastases (BM) can be associated with skeletal-related events (SRE) such as disabling pain, hypercalcemia, and bone instability that leads to pathological fractures or spinal cord compression. SRE contribute to high morbidity as well as, mortality, and have a negative economic impact. Modern management of BM integrates focal treatments (such as radiotherapy, surgery, and interventional radiology), orthoses, and antiresorptive and systemic oncological treatment. The choice of a metastasis-directed therapy depends on the objective of the treatment, the patient characteristics, and the complete assessment of the bone lesion (pain, neurological risk, and instability). In the narrative review present herein, we aim to provide an updated summary of the literature, with description of the advantages and disadvantages of current and emerging strategies in the multimodal treatment of BM and, based on these data, an updated algorithm for the management of BM.

Cookies & analyse de trafic

M LOUIS AIM

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal31

Revue générale6

Santé mentale / fatigue4

Épidémiologie & registres2

Revue / méta-analyse2

Anti-IL-231

Anti-TNF1

Biomarqueurs / Auto-Ac1

Corticothérapie1

Économie santé1

Génétique1

IA en rhumatologie1

Pédiatrie1

Recommandations1

SAPL1

Partager cette fiche